Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Common Equity: 2021-2024

Historic Common Equity for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $94,635.

  • ProQR Therapeutics N.V's Common Equity rose 143.18% to $66,719 in Q3 2025 from the same period last year, while for Sep 2025 it was $66,719, marking a year-over-year increase of 143.18%. This contributed to the annual value of $94,635 for FY2024, which is 111.37% up from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Common Equity stood at $94,635 for FY2024, which was up 111.37% from $44,772 recorded in FY2023.
  • ProQR Therapeutics N.V's 5-year Common Equity high stood at $135.0 million for FY2021, and its period low was $44,772 during FY2023.
  • For the 3-year period, ProQR Therapeutics N.V's Common Equity averaged around $22.7 million, with its median value being $94,635 (2024).
  • In the last 5 years, ProQR Therapeutics N.V's Common Equity plummeted by 99.93% in 2023 and then spiked by 111.37% in 2024.
  • ProQR Therapeutics N.V's Common Equity (Yearly) stood at $135.0 million in 2021, then crashed by 49.62% to $68.0 million in 2022, then tumbled by 99.93% to $44,772 in 2023, then skyrocketed by 111.37% to $94,635 in 2024.